NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT03157128 2025-10-20LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 3 FDA
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT00437372 2025-05-02Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer PatientsThomas Jefferson UniversityPhase 1 Completed39 enrolled
NCT04774952 2025-04-15Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Completed58 enrolled